Department of Defense (DOD) Fiscal Year 2006 (FY06) Chronic Myelogenous Leukemia Research Program (CMLRP) New Investigator Award (NIA)

The summary for the Department of Defense (DOD) Fiscal Year 2006 (FY06) Chronic Myelogenous Leukemia Research Program (CMLRP) New Investigator Award (NIA) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

Department of Defense (DOD) Fiscal Year 2006 (FY06) Chronic Myelogenous Leukemia Research Program (CMLRP) New Investigator Award (NIA): The intent of the NIA is to recognize and support the career transition and/or continued development of independent investigators in the field of CML research. Eligible investigators include those with MD, PhD, or MD-PhD degrees within 6 years of completing their last fellowship or postdoctoral training position who have innovative research ideas and new technologies applicable to clinical translational research in CML. Applicants with limited background in CML are strongly encouraged to have a collaborator who is experienced in the field of CML research. All NIA proposals must include preliminary data relevant to the proposed project but not necessarily from the field of CML research. The NIA has two significant features: (1) The intent to support clinical translational research in the field of CML research. Clinical translational research may incorporate different aspects of clinical research and is not limited to actual clinical trials, but must focus directly on translating basic science into treatments or therapeutics directly applicable to bedside care of CML patients. This feature is so highly sought by the CMLRP that research proposals not including a clinical transitional focus may be administratively withdrawn at the discretion of the Government. (2) The NIAs second significant feature lies in its intent to promote research that is uniquely innovative. Because innovation is often difficult to identify, the following offers a brief perspective of innovation as interpreted by the CMLRP. 1. Innovation: Innovation is a significant feature of the NIA. Research deemed innovative may represent a new paradigm, challenge existing paradigms, or look at existing problems from new perspectives. It is the responsibility of the investigator to clearly and explicitly articulate how the proposed research is innovative. Proposals may be innovative in a variety of ways, including the following: Study concept - investigation of a novel idea and/or unique research question that has the potential to advance the field of CML research in a significant way. Research method or technology - use of novel research methods or new technologies to address a research question that could not be addressed using conventional methods/techniques. Clinical interventions - use of a novel method or technology for preventing, diagnosing, or treating CML. Adaptations of existing methods or technologies - application or adaptation of existing methods or technologies for research or clinical purposes that are fundamentally different from those originally intended, and/or for use under novel research or clinical purposes. This list is intended to serve as a foundation on which to frame and present the innovative features of the proposal. Conversely, examples of research that is not innovative and will not be considered for funding under this mechanism include: Exploring a hypothesis in a different cell line. Using a published series of in vitro assays to further characterize a model system. Incorporating known biomarkers into in vitro or clinical models of CML. 2. Impact: Research that has high impact may significantly advance current methods, concepts, prevention, diagnosis, or treatment of CML or quality of life for patients. It is the responsibility of the investigator applicant to clearly and explicitly articulate the projects innovation and the impact it may have on the field of CML research.